4Tissue is redefining breast reconstruction with its advanced hydrogel tissue mimic technology that enhances the body's natural tissue regeneration process. Delivering natural and long-lasting results, it ushers in a new era of safe, effective and life-affirming solutions for women after battling breast cancer. “Our hydrogel platform isn’t just about reconstructing tissue, it’s redefining the future of soft-tissue regeneration,” says Dr. An Van Den Bulcke, chief executive officer a.i. and co-founder. “We make it safer, simpler and truly patient-centered.” Over 60 percent of women undergoing mastectomy in Europe choose reconstruction, yet current treatments are not optimal. Synthetic implants, though widely used, carry risks such as capsular contracture, implant rupture and potential systemic complications. Their limited lifespan often requires multiple replacement surgeries over a patient’s lifetime. Autologous flap procedures involve complex microsurgery, extended hospital stays of four to seven days, recovery periods lasting six to eight weeks, and visible scarring at both the donor and reconstruction sites. Autologous lipofilling, a process of grafting a patient’s own fat, offers a more natural and minimal invasive alternative, but with significant drawbacks. On average, only around 50 percent of the transferred volume is retained, often requiring two to eight procedures to achieve the desired result. It is assumed that many of the injected cells fail to survive due to factors such as shear stress during injection, leakage, poor integration into the host tissue, and limited nutrient supply at the target site. 4Tissue’s first-in-class, bioresorbable injectable hydrogel transcends these limitations by protecting and anchoring cells. By encapsulating a patient’s own adipose or stem cells within, it significantly enhances initial cell survival and allows the formation of new vasculature, accelerating tissue regeneration. Over approximately six months, the hydrogel gradually resorbs, leaving behind fully natural tissue without any foreign remnants. Because of high cell survival the procedure can be done in one-step with durable, natural results, avoiding the need for repeat interventions, hospitalization and anesthesia. The injectable format also minimises scarring and surgical complexity. .

Turning breakthrough science into life-changing impact, Adelphi Group crafts innovative strategies that cut through uncertainty, elevate value, and connect medicines with the people who need them most. As a powerhouse in the pharmaceutical and biopharma space, Adelphi helps companies move from early concepts to real-world impact through an approach that is as comprehensive and collaborative. A global, multi-perspective network and part of Omnicom Health, Adelphi supports the entire product development journey, from early-stage insight generation to post-launch value demonstration. With expertise spanning all therapeutic areas, including rare diseases, and a client roster of over 100 pharmaceutical companies worldwide, Adelphi stands out not just for its work’s breadth but also for its approach’s depth and cohesion. What truly sets Adelphi apart is its structure, which is carefully designed to mirror the development processes of its clients. Rather than offering fragmented services or siloed solutions, the company unites multiple disciplines under one roof, integrating its capabilities into a cohesive force that can respond to the evolving demands of pharmaceutical strategy. Its specialist companies operate with agility and autonomy, yet come together to deliver what the organization calls the “Power of Unity”, a deeper level of scientific understanding and strategic clarity that transcends individual silos. “We consistently deliver more strategic, impactful solutions throughout the product lifecycle, empowering clients to navigate uncertainty and achieve meaningful change,” says Stuart Cooper, CEO. .